Official Title
The Prognostic Value of IgM in Covid-19 Infection
Brief Summary

The primary objective of the research is to study the relation between the presence and/or the anti SARS-Co-V-2 IgM level in an early stage of COVID-19 infection, and theevolution of the illness.

Detailed Description

The secondary objective is to determinate in what manner response of IgM anti-SARS-Co-V-2
relates to patient's immunity statute, in regards to the other so-called humain "seasonal
coronavirus".

Unknown status
COVID-19
Eligibility Criteria

Inclusion Criteria:

- Patients ≥ 18 years;

- Have been diagnosed positive of SARS-CoV-2 in the Virological Laboratory of Ambroise
Paré hospital;

- Have been blood sampled between 1 day and 14 days from the first clinical syndromes,
and their collections of serum or plasma are conserved and accessible;

- Affiliated to the social security scheme or entitled;

- Informed and non-opposed to participating to the study.

Exclusion Criteria:

- Opposition of patient to participation to the study;

- Foreign patients under french AME scheme.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Locations

Not Provided

Contacts

Jean-Louis Gaillard, MD, PhD
+ 33 (0)1 49 09 55 40
jean-louis.gaillard@aphp.fr

Jean-Louis Gaillard, MD, PhD, Principal Investigator
Microbiological Laboratory - CHU Ambroise Paré - APHP

Assistance Publique - Hôpitaux de Paris
NCT Number
Keywords
Covid-19
anti SARS-Co-V-2 IgM
MeSH Terms
COVID-19